CJC-1295 + Ipamorelin Stack
The combination of CJC-1295 (no DAC) and ipamorelin is the most commonly prescribed growth hormone peptide stack in clinical anti-aging and hormone optimization. These two peptides work through different receptors to produce a stronger, more sustained growth hormone release than either one alone. CJC-1295 stimulates the GHRH receptor to initiate GH production, while ipamorelin stimulates the ghrelin receptor to amplify and extend that release. The result is a strong, pulsatile GH elevation that closely mimics youthful hormone patterns.
FormBlends Peptide Context
Reviewed May 14, 2026Treat Cjc 1295 Ipamorelin peptide guide as context for a safer next conversation. It should help with frame benefits, dosing, evidence strength, sourcing, and safety boundaries in one place, while keeping the reader focused on peptide therapy, evidence limits, provider oversight, and the difference between general information and personal medical advice.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
CJC-1295 + Ipamorelin Stack authority snapshot
CJC-1295 + Ipamorelin Stack is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Neither CJC-1295 nor ipamorelin is FDA approved. The combination is widely available through compounding pharmacies and is one of the most prescribed peptide protocols in anti-aging medicine.
Safety screen
Water retention during the first 2-4 weeks, Flushing or warmth after injection, Tingling in hands and feet should be reviewed in context.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for CJC-1295 + Ipamorelin Stack?
CJC-1295 + Ipamorelin Stack should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- CJC-1295 + Ipamorelin Stack
- Category
- Growth Hormone
- Evidence
- Meaningful evidence with limits
- FDA status
- Neither CJC-1295 nor ipamorelin is FDA approved. The combination is widely available through compounding pharmacies and is one of the most prescribed peptide protocols in anti-aging medicine.
Step 1
Check evidence level
CJC-1295 and ipamorelin are the most commonly prescribed GH secretagogue combination. Each has individual human data (CJC-1295 Phase 1/2 PK studies, ipamorelin Phase 2 safety trial). The combination targets two different receptor pathways simultaneously for stronger GH release. Clinical practice supports the combination, though no trial has tested them together head-to-head.
Review evidenceStep 2
Screen safety context
Water retention during the first 2-4 weeks, Flushing or warmth after injection, Tingling in hands and feet should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessGrowth hormone axis hub
CJC-1295 and ipamorelin pages should explain the GH-axis decision
CJC-1295 and ipamorelin are not best handled as generic performance peptides. The useful read is whether the goal involves sleep, body composition, recovery, or growth hormone signaling, and whether labs, contraindications, and expectations make the pathway reasonable.
Decision question for CJC-1295 + Ipamorelin Stack
Is the reader trying to optimize recovery, or are there symptoms that need endocrine evaluation first?
Peptide evidence layer
Evidence read
The strongest content should explain GHRH analog signaling, ghrelin receptor activity, IGF-1 context, why pulses matter, and why outcomes are not the same as direct growth hormone treatment.
Safety watch
A careful screen should consider diabetes risk, edema, carpal tunnel symptoms, cancer history, sleep apnea, headaches, elevated IGF-1, and whether symptoms point to another endocrine condition.
Conversion fit
The conversion path should route to provider review with lab context, sleep history, body-composition goals, and medication history instead of promising fast performance outcomes.
Last updated: April 3, 2026
Typical Dosage
CJC-1295 no DAC: 100-300 mcg combined with Ipamorelin: 200-300 mcg, injected subcutaneously 1-3 times daily. Most common protocol is a bedtime dose of both peptides combined. Many compounding pharmacies offer pre-mixed vials. Typical cycle length is 3-6 months with periodic breaks.
Administration
Subcutaneous injection
Typical Cost
$200-400/month. Pre-mixed combination vials are often more cost-effective than purchasing separately.
FDA Status
Neither CJC-1295 nor ipamorelin is FDA approved. The combination is widely available through compounding pharmacies and is one of the most prescribed peptide protocols in anti-aging medicine.
About CJC-1295 + Ipamorelin Stack
The CJC-1295 and ipamorelin combination is the most frequently prescribed growth hormone secretagogue protocol. It's used for anti-aging, body composition improvement, sleep quality, and recovery support.
The combination works because the two peptides activate different receptor pathways. CJC-1295 (a GHRH analog) binds to the GHRH receptor on pituitary somatotrophs, telling them to produce and release growth hormone. Ipamorelin (a ghrelin mimetic) binds to the ghrelin receptor (GHS-R1a) on the same cells, amplifying the release signal. Using both together produces a synergistic GH pulse that's significantly stronger than either compound alone.
Think of it like pressing the gas pedal (CJC-1295) while also putting the car in a lower gear (ipamorelin). Both actions increase speed, but through different mechanical pathways, and the combined effect is greater than either alone.
CJC-1295 comes in two versions. The "no DAC" version (modified GRF 1-29) has a half-life of about 30 minutes and produces a sharp GH pulse. The "with DAC" version has a half-life of 5-8 days due to albumin binding. Most practitioners prefer the no-DAC version for combination protocols because its short duration better mimics natural pulsatile GH release.
Ipamorelin was specifically chosen as the pairing partner because of its selectivity. Unlike GHRP-6 and GHRP-2 (older ghrelin mimetics), ipamorelin doesn't significantly raise cortisol or prolactin levels and doesn't cause the intense hunger that GHRP-6 triggers. A 1999 study in the European Journal of Endocrinology (PMID: 10601960) confirmed this selective GH release profile.
The standard protocol is CJC-1295 (no DAC) at 100-200 mcg plus ipamorelin at 200-300 mcg, both injected subcutaneously at the same time, typically before bed. Some practitioners add a second dose in the morning. The pre-bedtime timing amplifies the natural nocturnal GH surge, which accounts for the sleep quality improvements many users report.
Results from this combination are gradual. Body composition changes (more lean mass, less body fat, better skin quality) typically become noticeable at 3-6 months. Sleep improvements and recovery benefits often appear sooner, within 2-4 weeks.
Both compounds were restricted from US compounding in 2023 and reinstated in February 2026.
How CJC-1295 + Ipamorelin Stack Works
CJC-1295 and ipamorelin achieve synergy by activating two separate arms of the growth hormone release system simultaneously. CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, priming them for GH synthesis and secretion. Ipamorelin then binds to the GHS receptor (ghrelin receptor) on those same cells, amplifying the release signal. This dual stimulation produces a GH pulse that is 3-5 times larger than either peptide would produce alone. Importantly, ipamorelin does not significantly raise cortisol or prolactin, and the natural somatostatin feedback loop remains intact, preventing excessive or uncontrolled GH elevation.
Benefits
- Produces stronger GH release than either peptide alone
- Maintains natural pulsatile GH pattern without suppressing pituitary function
- Improves body composition by increasing lean mass and reducing fat
- Enhances sleep quality, particularly deep slow-wave sleep
- Supports skin elasticity, collagen production, and hair quality
- Accelerates recovery from exercise and physical stress
- Improves bone density with sustained use
- Ipamorelin component prevents cortisol and prolactin elevation
PubMed evidence trail
Research sources used to frame this page
For CJC-1295 + Ipamorelin Stack, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Potential Side Effects
- Water retention during the first 2-4 weeks
- Flushing or warmth after injection
- Tingling in hands and feet
- Headache
- Mild joint stiffness at higher doses
- Increased vivid dreaming
Stacking Options
CJC-1295 + Ipamorelin Stack is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Research Status
Both peptides have moderate individual clinical research. The combination is supported by strong pharmacological rationale based on the dual-receptor mechanism. Extensive clinical use in anti-aging and functional medicine practices with a well-characterized safety profile.
Get CJC-1295 + Ipamorelin Stack from FormBlends
Pharmaceutical-grade cjc-1295 + ipamorelin stack with free physician consultation.
View Product DetailsFind a CJC-1295 + Ipamorelin Stack Clinic Near You
Browse peptide therapy clinics in your area that offer cjc-1295 + ipamorelin stack treatments.
Find Peptide Clinics